



The San Francisco Hepatitis C Elimination Initiative, End Hep C SF, is a multi-sector collective impact initiative that utilizes evidence-based practices, community wisdom, and the creative leveraging of resources to work toward hepatitis C elimination in San Francisco.^{1,2,3}

San Francisco has a history of innovative and ambitious public health efforts. End Hep C SF emerges from that history to tackle an epidemic that kills more Americans than the deaths from sixty other reportable infectious diseases, including HIV, pneumococcal disease, and tuberculosis, combined.^{4,5}

Vision Statement

San Francisco is profoundly impacted by the hepatitis C virus (HCV), a communicable liver disease that is a significant driver of morbidity, liver cancer, and death. The availability of highly effective, well-tolerated oral HCV therapy gives us the remarkable ability to cure HCV in nearly all people living with the virus. We now have the tools to greatly reduce the negative health consequences of HCV, to break the cycle of forward transmission through cure as prevention, and to ultimately eliminate HCV in San Francisco. To realize the potential of modern HCV therapy, we have established End Hep C SF. Our long-term strategic plan is to lay the foundation for HCV elimination in San Francisco through a comprehensive approach based on three pillars:

1. Citywide community-based HCV testing for highly impacted populations paired with augmented HCV surveillance infrastructure to track the HCV epidemic and progress towards elimination;
2. Linkage to care and treatment access for all people living with HCV;
3. Prevention of new HCV infections and reinfection in those cured of HCV.

1. Elimination refers to the cessation of transmission of a disease in a single country, continent, or other limited geographic area, rather than global eradication (e.g., polio in the Americas).
2. Collective Impact is a framework to tackle deeply entrenched and complex social problems. It is an innovative and structured approach to making collaboration work across government, business, philanthropy, non-profit organizations and citizens to achieve significant and lasting social change.
3. <http://www.collaborationforimpact.com>
4. Ly KN, Hughes EM, Jiles RB, Holmberg SD. Rising Mortality Associated With Hepatitis C Virus in the United States, 2003–2013 Clin Infect Dis. first published online March 1, 2016 doi:10.1093/cid/ciw111
5. <http://www.cdc.gov/media/releases/2016/p0504-hepc-mortality.html>

Community Partners

UCSF Alliance Health Project
BAART Programs
Bayview Hunters Point Foundation
California Hepatitis Alliance (CalHEP)
Drug Policy Alliance
Facente Consulting
Glide Foundation
Harm Reduction Coalition
HealthRIGHT 360
Hellman Foundation
Homeless Youth Alliance
Kaiser Permanente
Larkin Street Youth Services
Mission Neighborhood Health Center
Mission Wellness Pharmacy
Native American Health Center
Opiate Treatment Outpatient Program (OTOP)
Positive Health Program
Project Open Hand
RTI International
San Francisco AIDS Foundation
San Francisco Community Health Center
San Francisco Cancer Initiative (SF CAN)
San Francisco Department of Public Health
San Francisco Health Plan
San Francisco Hepatitis C Task Force
Shanti Project
South of Market Health Center
St. James Infirmary
Sutter Health
UCSF
UCSF NOW (No One Waits) Study
The UFO Study
Walgreens
Zuckerberg San Francisco General Hospital



Committees and Work Groups

End Hep C SF is guided by a Coordinating Committee and four topic-specific work groups that recommend action steps to the Coordinating Committee. The Work Groups are comprised of individuals affected by HCV, healthcare and social service providers, community advocates, health department representatives, and other stakeholders. The Work Groups include: Policy & Advocacy; Prevention, Testing & Linkage; Research & Surveillance; and Treatment Access. The lifeblood of our initiative is our community members, especially those who have lived experience with HCV. We continuously strive to improve representation and build leadership in our initiative so that community members guide this work at all levels, and we believe in appropriate compensation for their labor and expertise.

Coordinating Committee Members

Katie Burk, MPH - SFDPH
 Joanne Kay - End Hep C SF
 Shelley Facente, MPH - Facente Consulting
 Perry Rhodes III - Alliance Health Project
 Jordan Akerley - The Shanti Project
 Amy Rodriguez - Glide
 Annie Luetkemeyer, MD, UCSF
 Jennifer Price, MD - UCSF

Meghan Morris, PhD - UCSF / UFO Study
 Melissa Sanchez, PhD - SFDPH
 Robin Roth - San Francisco Hepatitis C Task Force
 Pauli Gray - San Francisco Hepatitis C Task Force
 Isaac Jackson, Urban Survivors Union
 Miss Ian - Drug Users' Union
 Brian Clear, MD - BAART Programs
 Courtney Mulhern-Pearson, MPH - SF AIDS Fdn

For more information please visit endhepcsf.org. Working together we can end hepatitis C in San Francisco!



End Hep C SF Community Partner Sign-On Notification

_____ shares the vision of hepatitis C elimination in San Francisco driven by broad-based prevention, testing, linkage, and treatment strategies. Our organization partners with End Hep C SF and will offer staff time in initiative meetings and expertise on the needs of impacted community members we serve. We believe every San Franciscan deserves the opportunity to prevent hepatitis C infection, know their hepatitis C status, and receive hepatitis C treatment if needed.

Signed,

Name, Title

Organization

Date

Return to Katie Burk, Viral Hepatitis Coordinator, SFDPH, at katie.burk@sfdph.org. cc.
Joanne Kay, Program Coordinator at End Hep C SF at jkay@endhepcsf.org. For more information please visit www.endhepcsf.org. Working together we can end hepatitis C in San Francisco!